Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMLBYRA)

Drug Name
ADX N05 Drug Info
Indication
Disease Entry ICD 11 Status REF
Mood disorder 6A60-6E23 Phase 3 [1]
Excessive daytime sleepiness MG42 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMLBYRA

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor sigma 1 (OPRS1) TT5TPI6 SGMR1_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Opioid receptor sigma 1 (OPRS1) DTT SIGMAR1 7.092 5.716 5.411 6.434
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Mood disorder
ICD Disease Classification 6A60-6E23
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Opioid receptor sigma 1 (OPRS1) DTT SIGMAR1 2.77E-06 -0.12 -0.62
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030225)
2 Clinical pipeline report, company report or official report of SK BioPhamaceuticals.